Andries M. Bergman

9.3k total citations
158 papers, 4.5k citations indexed

About

Andries M. Bergman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Andries M. Bergman has authored 158 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Pulmonary and Respiratory Medicine, 63 papers in Oncology and 52 papers in Molecular Biology. Recurrent topics in Andries M. Bergman's work include Prostate Cancer Treatment and Research (86 papers), Radiopharmaceutical Chemistry and Applications (37 papers) and Cancer Treatment and Pharmacology (24 papers). Andries M. Bergman is often cited by papers focused on Prostate Cancer Treatment and Research (86 papers), Radiopharmaceutical Chemistry and Applications (37 papers) and Cancer Treatment and Pharmacology (24 papers). Andries M. Bergman collaborates with scholars based in Netherlands, United States and Germany. Andries M. Bergman's co-authors include Godefridus J. Peters, Herbert M. Pinedo, G. Veerman, Catharina M. Kuiper, C.J.A. van Moorsel, Wilbert Zwart, C.L. van der Wilt, Henk G. van der Poel, Boudewijn J.M. Braakhuis and Judith R. Kroep and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Cell.

In The Last Decade

Andries M. Bergman

151 papers receiving 4.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andries M. Bergman Netherlands	33	1.8k	1.6k	1.6k	797	725	158	4.5k
Peter J. Van Veldhuizen United States	34	1.4k 0.8×	1.3k 0.8×	1.4k 0.9×	827 1.0×	374 0.5×	96	3.6k
Francesco Caponigro Italy	28	2.3k 1.3×	1.2k 0.8×	2.0k 1.2×	552 0.7×	594 0.8×	101	4.6k
Antonio Jimeno United States	36	3.1k 1.7×	1.4k 0.9×	2.3k 1.4×	921 1.2×	552 0.8×	128	5.2k
Michael L. Cher United States	42	2.0k 1.1×	2.5k 1.5×	1.9k 1.1×	1.6k 2.0×	590 0.8×	165	5.5k
Ignacio Durán Spain	37	2.3k 1.3×	1.4k 0.8×	1.5k 0.9×	562 0.7×	1.6k 2.2×	206	4.8k
Akira Yokomizo Japan	40	1.6k 0.9×	1.9k 1.1×	2.7k 1.6×	849 1.1×	1.1k 1.5×	192	5.3k
Gaetano Facchini Italy	32	1.2k 0.7×	1.2k 0.7×	1.1k 0.7×	684 0.9×	685 0.9×	189	3.4k
Markus Borner Switzerland	43	3.0k 1.7×	1.8k 1.1×	1.8k 1.1×	847 1.1×	1.1k 1.6×	126	5.6k
Young E. Whang United States	39	1.7k 0.9×	1.5k 0.9×	3.2k 2.0×	874 1.1×	375 0.5×	101	5.6k
Giandomenico Roviello Italy	33	1.9k 1.0×	2.0k 1.2×	1.5k 0.9×	801 1.0×	923 1.3×	262	4.6k

Countries citing papers authored by Andries M. Bergman

Since Specialization

Citations

This map shows the geographic impact of Andries M. Bergman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andries M. Bergman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andries M. Bergman more than expected).

Fields of papers citing papers by Andries M. Bergman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andries M. Bergman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andries M. Bergman. The network helps show where Andries M. Bergman may publish in the future.

Co-authorship network of co-authors of Andries M. Bergman

This figure shows the co-authorship network connecting the top 25 collaborators of Andries M. Bergman. A scholar is included among the top collaborators of Andries M. Bergman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andries M. Bergman. Andries M. Bergman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Groenland, Stefanie L., Sil Kordes, Andries M. Bergman, et al.. (2025). Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients. British Journal of Cancer. 132(7). 635–642. 1 indexed citations

Vis, Daniël J., Edwin Cuppen, Niven Mehra, et al.. (2025). Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications. Genome Medicine. 17(1). 24–24. 1 indexed citations

Siefert, Joseph C., Liesbeth Hoekman, Simon Linder, et al.. (2025). TRIM33 loss reduces androgen receptor transcriptional output and H2BK120 ubiquitination. Communications Biology. 8(1). 1043–1043.

Barros, Hilda A. de, André N. Vis, Andries M. Bergman, et al.. (2023). Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options. Cancers. 15(11). 2962–2962. 2 indexed citations

Linder, Simon, Tesa Severson, Ekaterina Nevedomskaya, et al.. (2023). Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor–driven Programs. European Urology. 84(5). 455–460. 3 indexed citations

Chesner, Lisa N., Julie N. Graff, Fanny Polesso, et al.. (2023). Abstract B041: AR suppresses MHC Class I expression and T-cell response in prostate cancer. Cancer Research. 83(11_Supplement). B041–B041. 2 indexed citations

Petrylak, Daniel P., Raffaele Ratta, Nobuaki Matsubara, et al.. (2023). Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(6_suppl). 129–129. 1 indexed citations

Westgeest, Hans M., Alfons J.M. van den Eertwegh, R. Jeroen A. van Moorselaar, et al.. (2021). Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. Clinical Genitourinary Cancer. 20(1). 43–52. 2 indexed citations

Siefert, Joseph C., B. Cioni, Mauro J. Muraro, et al.. (2021). The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics. Molecular Cancer Research. 19(10). 1778–1791. 22 indexed citations

10.

Montfoort, Maurits L. van, Nick van Dijk, Ingrid Hofland, et al.. (2021). A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer. Clinical Genitourinary Cancer. 20(2). e173–e179. 1 indexed citations

11.

Shafi, Ayesha A., Christopher McNair, Jennifer J. McCann, et al.. (2021). The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. Nature Communications. 12(1). 401–401. 79 indexed citations

12.

Groenland, Stefanie L., Merel van Nuland, Andries M. Bergman, et al.. (2020). Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. European Journal of Cancer. 130. 32–38. 15 indexed citations

13.

Otten, Hans-Martin, et al.. (2019). Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice. Drugs & Aging. 36(4). 379–385. 5 indexed citations

14.

Dorlo, Thomas P. C., et al.. (2019). Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. Pharmaceutical Research. 36(12). 181–181. 6 indexed citations

15.

Singh, Abhishek A., Karianne Schuurman, Ekaterina Nevedomskaya, et al.. (2018). Optimized ChIP-seq method facilitates transcription factor profiling in human tumors. Life Science Alliance. 2(1). e201800115–e201800115. 28 indexed citations

16.

Nuland, Merel van, Andries M. Bergman, Hilde Rosing, et al.. (2018). Impact of age on exposure to oral antiandrogen therapies in clinical practice. Prostate Cancer and Prostatic Diseases. 22(1). 168–175. 6 indexed citations

17.

Nieuweboer, Annemieke J.M., Anne‐Joy M. de Graan, Paul Hamberg, et al.. (2016). Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study. Clinical Cancer Research. 23(7). 1679–1683. 12 indexed citations

18.

Wiel, Mark A. van de, José Luís Costa, Kees Smid, et al.. (2005). Expression Microarray Analysis and Oligo Array Comparative Genomic Hybridization of Acquired Gemcitabine Resistance in Mouse Colon Reveals Selection for Chromosomal Aberrations. Cancer Research. 65(22). 10208–10213. 24 indexed citations

19.

Wilt, C.L. van der, Judith R. Kroep, Andries M. Bergman, et al.. (2002). The Role of Deoxycytidine Kinase in Gemcitabine Cytotoxicity. Advances in experimental medicine and biology. 486. 287–290. 25 indexed citations

20.

Bergman, Andries M., Herbert M. Pinedo, Gijsbert Veerman, Catharina M. Kuiper, & Godefridus J. Peters. (1998). Increased Sensitivity to Gemcitabine of P-gP and MRP Overexpressing Human Non-Small Cell Lung Cancer Cell Lines. Advances in experimental medicine and biology. 431. 591–594. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact